Patents by Inventor George Georgiou

George Georgiou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220380832
    Abstract: Provided are methods for the identification of mutant kinases that are resistant to inhibition by a kinase inhibitor. In some embodiments, the methods may be used to assess a test compound or kinase inhibitor for the risk of the development of resistance in vivo, e.g., during clinical administration to treat a disease such as a cancer.
    Type: Application
    Filed: January 3, 2022
    Publication date: December 1, 2022
    Applicant: Research Development Foundation
    Inventors: Brent IVERSON, George GEORGIOU, Joseph DESAUTELLE, Joseph TAFT
  • Publication number: 20220275099
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Inventors: George GEORGIOU, Everett STONE, Nicholas MARSHALL, John BLAZECK, Wei-Cheng LU
  • Patent number: 11426464
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: August 30, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Patent number: 11332538
    Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc?RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: May 17, 2022
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee
  • Patent number: 11236380
    Abstract: Provided are methods for the identification of mutant kinases that are resistant to inhibition by a kinase inhibitor. In some embodiments, the methods may be used to assess a test compound or kinase inhibitor for the risk of the development of resistance in vivo, e.g., during clinical administration to treat a disease such as a cancer.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 1, 2022
    Assignee: Research Development Foundation
    Inventors: Brent Iverson, George Georgiou, Joseph Desautelle, Joseph Taft
  • Publication number: 20210386838
    Abstract: Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-?-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 16, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE, Wei-Cheng LU
  • Publication number: 20210347891
    Abstract: In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
    Type: Application
    Filed: June 14, 2021
    Publication date: November 11, 2021
    Applicant: Research Development Foundation
    Inventors: George GEORGIOU, Chang-Han LEE, Tae Hyun KANG
  • Patent number: 11168142
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Publication number: 20210213059
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: August 18, 2020
    Publication date: July 15, 2021
    Inventors: George GEORGIOU, Everett STONE
  • Patent number: 11059892
    Abstract: In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
    Type: Grant
    Filed: August 11, 2018
    Date of Patent: July 13, 2021
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee, Tae Hyun Kang
  • Publication number: 20210207110
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: March 2, 2017
    Publication date: July 8, 2021
    Inventors: George GEORGIOU, Everett STONE, John BLAZECK
  • Patent number: 11033612
    Abstract: Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-?-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 15, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Wei-Cheng Lu
  • Patent number: 11025481
    Abstract: Technologies are provided for correlating alert messages using placeholder correlation records. When a network alert message is received, a network component associated with the alert can be identified and a correlation record can be created that is associated with the identified network component. A model of the computer network can be used identify another network component that is related to the identified network component. If a correlation record for the related component does not exist, then a placeholder correlation record for the related component can be created. If another alert message is received that is associated with another component that is also related to the same component, then the placeholder correlation record can be used to correlate the alert messages. An event message can be generated that indicates an occurrence of a network event involving the related component associated with the placeholder correlation record.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 1, 2021
    Assignee: Amazon Technologies, Inc.
    Inventors: Andreas Louca, Toni Pivcevic, George Georgiou, Filip Boltuzic
  • Publication number: 20210128703
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Applicant: Aerase, Inc.
    Inventors: George Georgiou, Everett Stone
  • Patent number: 10965518
    Abstract: Technologies are provided for correlating alert messages using correlation domains. Alert messages can be received that are related to computer network components. The alert messages can be partitioned using separate correlation domains and analyzed by separate alert processors. When an alert message is received, it can be analyzed to determine a correlation domain with which the alert message is associated. The alert message can then be correlated with other alert messages associated with the correlation domain, and alert messages that are not associated with the correlation domain can be ignored. Groups of alert messages associated with different correlation domains can be correlated independently by different alert processors. Events generated by an alert processor can include correlation domain information. Events associated with different correlation domains can be handled differently.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: March 30, 2021
    Assignee: Amazon Technologies, Inc.
    Inventors: Andreas Louca, Toni Pivcevic, George Georgiou, Filip Boltuzic
  • Patent number: 10865403
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cancer and cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Shira Cramer
  • Publication number: 20200338197
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 29, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE
  • Patent number: 10773317
    Abstract: A rotating cutting tool that is internally cooled by cryogenic coolant, the rotating cutting tool has a cylindrical body including: a central bore that extends along a longitudinal axis of the cylindrical body; a plurality of cold flow delivery paths formed from radial bores that fluidly communicate with and extend radially-outwardly from the central bore; longitudinal grooves that are formed along an outer surface of the cylindrical body extending along the longitudinal axis and fluidly communicating with the radial bores; a bushing having an inner diameter closely conforming to the outer surface of the cylindrical body allowing the bushing to concentrically fit over the cylindrical body and the longitudinal grooves to form longitudinal passageways extending from the radial bores to one or more exhaust ports formed in the bushing proximate a rear face of the cylindrical body; and a plurality of flutes for cutting a workpiece each having a cutting edge formed from the bushing.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 15, 2020
    Assignee: 5ME IP, LLC
    Inventor: George Georgiou
  • Patent number: 10772913
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Publication number: 20200270704
    Abstract: Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.
    Type: Application
    Filed: October 29, 2018
    Publication date: August 27, 2020
    Inventors: Gregory C. IPPOLITO, Jonathan R. MCDANIEL, William N. VOSS, George GEORGIOU